SHANG.FOS.PHARM.GR.H YC 1 (08HH) — Net Asset Momentum
SHANG.FOS.PHARM.GR.H YC 1 (08HH) recorded a net asset momentum of 3.2% as of December 2025, with net assets of €61.84 Billion EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See SHANG.FOS.PHARM.GR.H YC 1 (08HH) shareholders funds for net asset value and shareholders' equity analysis.
YoY Momentum
Current Net Assets
Years of Data
Country
SHANG.FOS.PHARM.GR.H YC 1 Net Asset Momentum (2021–2025)
This chart tracks SHANG.FOS.PHARM.GR.H YC 1's year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is +3.2%, with net assets of €61.84 Billion EUR as of December 2025. For live market cap and overall valuation, see 08HH company net worth.
Annual Net Asset History for SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
The table below shows the complete annual net asset history for SHANG.FOS.PHARM.GR.H YC 1 from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. Check SHANG.FOS.PHARM.GR.H YC 1 tangible book value ratio to evaluate the tangible quality of the company's equity base.
| Year | Net Assets (EUR) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | €61.84 Billion | €120.05 Billion | €58.21 Billion | ▲ +3.2% |
| 2024 | €59.93 Billion | €117.46 Billion | €57.53 Billion | ▲ +5.9% |
| 2023 | €56.62 Billion | €113.47 Billion | €56.85 Billion | ▲ +4.6% |
| 2022 | €54.11 Billion | €107.16 Billion | €53.05 Billion | ▲ +11.8% |
| 2021 | €48.38 Billion | €93.31 Billion | €44.93 Billion | — |